Decoding the selective chemical modulation of CYP3A4.

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Drug-drug interactions are common with polypharmacy.
• Cytochrome P450 3A4 (CYP3A4) is a key enzyme in drug metabolism.
• Pan-CYP3A inhibitors like ritonavir are used but lack selectivity.

Purpose of the Study:

• To develop novel inhibitors selective for CYP3A4 over CYP3A5.
• To understand the structural basis for CYP3A4 selectivity.
• To guide the design of improved CYP3A4-selective inhibitors.

Main Methods:

• High-throughput screening to identify initial inhibitor scaffolds.
• Structural, functional, and computational analyses of enzyme-inhibitor interactions.
• Structure-guided design and synthesis of novel analogs.

Main Results:

• Identified selective CYP3A4 inhibitor scaffolds.
• Elucidated structural determinants (C-terminal loop, binding surfaces) for selectivity.
• Validated structure-based design with analogs showing high CYP3A4 vs. CYP3A5 selectivity.
• Demonstrated selectivity against other major Cytochrome P450 enzymes.

Conclusions:

• Selective inhibition of CYP3A4 is feasible.
• Differential structural features between CYP3A4 and CYP3A5 enable selectivity.
• Provides a framework for designing next-generation CYP3A4-selective inhibitors for safer drug combinations.